AION Labs and BioMed X Launch Global AI Initiative for Drug Discovery

AION Labs, in collaboration with BioMed X, has announced in a press release the launch of a global call for applications aimed at forming a new startup focused on generative AI for novel target combinations. This initiative seeks to attract computational biologists, biomedical scientists, and AI experts to develop an AI-driven platform that identifies and validates molecular target combinations for multispecific biologic drugs.

The venture studio, based in Rehovot, Israel, and supported by pharmaceutical giants such as AstraZeneca, Merck, and Pfizer, aims to revolutionize drug discovery by moving beyond single-target approaches. The new platform will prioritize target combinations based on disease relevance and biomarker predictability, particularly in therapeutic areas like oncology and cardiovascular-kidney-metabolic diseases.

Interested candidates are invited to submit proposals through the BioMed X Career Space by May 5, 2025. The initiative underscores the potential of AI to transform biologic drug design by uncovering intricate molecular interactions and optimizing target combinations that traditional methods might overlook.